Cargando…
Risk Factors for Poor Adherence to Betaferon(®) Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome
INTRODUCTION: Adherence to treatment, including early treatment discontinuation, in patients with multiple sclerosis or clinically isolated syndrome can be affected by: treatment tolerability, route of drug administration, patient age, disease duration, comorbidities, medical care, and support from...
Autores principales: | Jernas, Łukasz, Wencel, Jacek, Wiak, Andrzej, Bieniek, Marek, Bartosik-Psujek, Halina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047441/ https://www.ncbi.nlm.nih.gov/pubmed/27695075 http://dx.doi.org/10.1371/journal.pone.0157950 |
Ejemplares similares
-
Course of therapy in patients with active relapsing-remitting multiple sclerosis despite first-line treatment
por: Bartosik-Psujek, Halina, et al.
Publicado: (2023) -
Betaferon® – Ab Ovo
por: Limmroth, Volker
Publicado: (2013) -
Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy
por: Jaworski, Jacek, et al.
Publicado: (2012) -
Antibodies to Interferon beta in Patients with Multiple Sclerosis Receiving CinnoVex, Rebif, and Betaferon
por: Zare, Nasrin, et al.
Publicado: (2013) -
Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence
por: Bayas, Antonios, et al.
Publicado: (2015)